Clinical Trial Update: Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rosuvastatin to reduce myocardial damage and systemic inflammation during coronary angioplasty in patients with stable coronary arter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stable Coronary Artery Disease

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: G. d'Annunzio University | Conditions: Stable Coronary Artery Disease Undergoing PCI | Phase 3 | Status: TERMINATED